CASI Pharmaceuticals, Inc.
CASIF · PNK
Market closed$0.170000$0.020000 (+13.33%)After hours $0.170000 · 0.00%
Key statistics
Previous close$0.150000
Open$0.166000
Day high$0.170000
Day low$0.134400
52-week high$3.09
52-week low$0.050000
Market cap3.49M
Volume1.00
Average volume9.41K
P/E ratio-0.06
Forward P/E—
EPS-2.68
Dividend yield0.00%
Market context
Why it moved
CASIF shares surged today likely driven by speculative buying interest and low-float momentum, as no specific company news was identified but the stock saw strong upward price action with increased buying pressure pushing it to its daily high.
What is happening
Recent company-specific developments and publisher coverage.
Investing News Network · February 25, 2026CASI Pharmaceuticals Receives the Delisting Decision From the Nasdaq Hearings PanelStock Titan · February 25, 2026CASI loses Nasdaq listing, pursues OTC trading after panel rulingInvesting News Network · January 12, 2026CASI Pharmaceuticals Announces Update and Additional Results from Phase 1 Study of CID-103 in Adult Patients with Chronic Immune ThrombocytopeniaNewswire.com · July 21, 2025CASI Pharmaceuticals Appoints David Cory as Chief Executive Officer to Lead U.S. Company Focused on Clinical Development of CID-103, a Potential Best in Class Anti-CD38 ProgramPR Newswire · June 26, 2024CASI Pharmaceuticals Announces $15 Million Private Placement Financing by Venrock Healthcare Capital Partners, Foresite Capital, Panacea Venture and Dr. Wei-Wu HeClinical Trials Arena · February 19, 2024CASI begins dosing lymphoma patients with pralatrexate in China Benzinga · February 26, 2026What Drove CASI Pharmaceuticals' 24% Rise After Hours? Benzinga · February 25, 2026CASI Pharmaceuticals To Be Delisted From Nasdaq, Effective Feb. 26 Benzinga · January 22, 2026CASI Pharmaceuticals Fails To Renew FOLOTYN Import License In China, Halting Sales Benzinga · January 15, 2026CASI Pharmaceuticals Gets China National Medical Products Administration's Approval To Start Phase1/2 Clinical Study For CID-103 In Adults With Chronic Active Renal Allograft Antibody-Mediated Rejection Benzinga · December 8, 2025CASI Pharmaceuticals Highlights Results From CID-103 Immune Thrombocytopenia Study Study At Annual ASH Meeting Benzinga · September 3, 2025HC Wainwright & Co. Reiterates Buy on CASI Pharmaceuticals, Maintains $4 Price Target Benzinga · August 29, 202512 Health Care Stocks Moving In Friday's After-Market Session Benzinga · August 29, 2025CASI Pharmaceuticals Q2 EPS $(0.86) Misses $(0.47) Estimate, Sales $4.175M Miss $6.300M Estimate